



Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys

Gary A Giovino, Sara A Mirza, Jonathan M Samet, Prakash C Gupta, Martin J Jarvis, Neeraj Bhala, Richard Peto, Witold Zatonski, Jason Hsia, Jeremy Morton, Krishna M Palipudi, Samira Asma, for The GATS Collaborative Group*

Summary

Lancet 2012; 380: 668–79

See [Comment](#) page 629

*Members listed in the appendix

Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA (Prof G A Giovino PhD); Global Tobacco Control Branch, Office on Smoking and Health, Centers for Disease Control and Prevention, Atlanta, GA, USA (S A Mirza PhD, J Hsia PhD,

J Morton MS, K M Palipudi PhD, S Asma DDS); Department of Preventive Medicine, Keck School of Medicine, Institute for Global Health, University of Southern California, Los Angeles, CA, USA (Prof J M Samet MD); Healix-

Sekhsaria Institute for Public Health, CBD Belapur Navi Mumbai, India (P C Gupta ScD); Department of Epidemiology and Public Health, University College London, London, UK (Prof M J Jarvis DSc);

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK (N Bhala MRCP, Prof R Peto MSc);

Department of Cancer Epidemiology and Prevention, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (Prof W Zatonski MD); and European Health Inequalities Observatory, Institute of Rural Health, Lublin, Poland (W Zatonski)

Correspondence to: Prof Gary A Giovino, Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, The State University of New York, 310 Kimball Tower, Buffalo, NY 14214-8028, USA ggiovino@buffalo.edu

Background Despite the high global burden of diseases caused by tobacco, valid and comparable prevalence data for patterns of adult tobacco use and factors influencing use are absent for many low-income and middle-income countries. We assess these patterns through analysis of data from the Global Adult Tobacco Survey (GATS).

Methods Between Oct 1, 2008, and March 15, 2010, GATS used nationally representative household surveys with comparable methods to obtain relevant information from individuals aged 15 years or older in 14 low-income and middle-income countries (Bangladesh, Brazil, China, Egypt, India, Mexico, Philippines, Poland, Russia, Thailand, Turkey, Ukraine, Uruguay, and Vietnam). We compared weighted point estimates and 95% CIs of tobacco use between these 14 countries and with data from the 2008 UK General Lifestyle Survey and the 2006–07 US Tobacco Use Supplement to the Current Population Survey. All these surveys had cross-sectional study designs.

Findings In countries participating in GATS, 48·6% (95% CI 47·6–49·6) of men and 11·3% (10·7–12·0) of women were tobacco users. 40·7% of men (ranging from 21·6% in Brazil to 60·2% in Russia) and 5·0% of women (0·5% in Egypt to 24·4% in Poland) in GATS countries smoked a tobacco product. Manufactured cigarettes were favoured by most smokers (82%) overall, but smokeless tobacco and bidis were commonly used in India and Bangladesh. For individuals who had ever smoked daily, women aged 55–64 years at the time of the survey began smoking at an older age than did equivalently aged men in most GATS countries. However, those individuals who had ever smoked daily and were aged 25–34 years when surveyed started to do so at much the same age in both sexes. Quit ratios were very low (<20% overall) in China, India, Russia, Egypt, and Bangladesh.

Interpretation The first wave of GATS showed high rates of smoking in men, early initiation of smoking in women, and low quit ratios, reinforcing the view that efforts to prevent initiation and promote cessation of tobacco use are needed to reduce associated morbidity and mortality.

Funding Bloomberg Philanthropies' Initiative to Reduce Tobacco Use, Bill and Melinda Gates Foundation, Brazilian and Indian Governments.

Introduction

Tobacco use has long been a leading contributor to premature death, and causes about 9% of deaths worldwide.¹ Presently, the burden of tobacco use is greatest in high-income countries (18% of deaths are attributable to tobacco use), intermediate in middle-income countries (11%), and lowest in low-income countries (4%).¹ However, because rates of smoking are increasing in many low-income and middle-income countries (and decreasing in most high-income countries), the proportion of deaths from tobacco use could increase in low-income and middle-income countries as the number of tobacco-attributable deaths increases.^{1,2} According to WHO, nearly 6 million people die from tobacco-related causes every year.² If present patterns of use persist, tobacco use could cause as many as 1 billion premature deaths globally during the 21st century.²

Although most of the tobacco that is consumed throughout the world is in the form of manufactured cigarettes, it is also smoked in other products, such as

cigars, cigarillos, pipes, waterpipes, kreteks (clove cigarettes), bidis (tobacco in a tendu or temburni leaf that is tied with a cotton thread), and papirosy (cardboard tube-tipped cigarettes).³ Waterpipes are commonly used in Middle Eastern countries and some Asian countries. Kreteks are the dominant tobacco product consumed in Indonesia and bidis are smoked widely in the Indian subcontinent (Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka). Papirosy are smoked in Russia. Many types of smokeless tobacco products exist. Various forms of loose-leaf chewed tobacco are commonly consumed in the Indian subcontinent. For example, betel quid is made of tobacco, areca nut, slaked lime, and flavouring agents, all of which are wrapped in a betel leaf. Snuff (finely-chopped tobacco) is used in many countries and in some is branded with the names of leading cigarette varieties.

As for any major cause of disease, monitoring of tobacco use around the world is imperative. Accurate documentation of tobacco use by population-based surveys

facilitates understanding of disease patterns, provides an indication of the effectiveness of tobacco-control strategies and how they should be changed, and points to programmatic and research needs.⁴ The Global Tobacco Surveillance System was created by WHO, the US Centers for Disease Control and Prevention (CDC), and the Canadian Public Health Association⁵ “to enhance country capacity to design, implement and evaluate tobacco-control interventions, and monitor key articles of the WHO’s Framework Convention on Tobacco Control and components of the WHO MPOWER technical package.”⁶ Such activities are required by WHO’s Framework Convention on Tobacco Control,⁷ which is a broad treaty for global tobacco control. We report indicators of use and cessation from the first wave of the Global Adult Tobacco Survey (GATS), which was recently undertaken in 14 low-income and middle-income countries (Bangladesh, Brazil, China, Egypt, India, Mexico, Philippines, Poland, Russia, Thailand, Turkey, Ukraine, Uruguay, and Vietnam) that collectively contribute to most of the disease burden attributable to tobacco use. For comparison, we include data from nationally representative surveys in the UK and USA, and thus provide nationally representative data on tobacco use in 16 countries with a total population of about 3 billion individuals aged 15 years or older.

Methods

Study design and participants

Detailed descriptions of GATS,^{8,9} the UK General Lifestyle Survey,¹⁰ and the US Tobacco Use Supplement to the Current Population Survey¹¹ (hereafter referred to as the Tobacco Use Supplement) are available elsewhere (appendix p 2). Even though the General Lifestyle Survey did not sample in Northern Ireland, we refer to it as a UK survey for reasons of simplicity.

GATS is a household-based survey, designed to obtain nationally representative data in low-income and middle-income countries for the tobacco use behaviours of civilian, non-institutionalised individuals aged 15 years and older.^{8,9} Wave 1 focused on countries with large numbers of tobacco users and included Uruguay to help assess its recent tobacco-control activities. Residents from all regions of every nation were eligible to be sampled, apart from those living in remote or dangerous areas, as determined by each country’s implementing agency. A minimum sample size of 8000 households in each country was recommended so that any prevalence estimate of less than 40% would have a 95% margin of error of no greater than 3 percentage points.⁸ Sample sizes in the four countries that made regional estimates (India, Brazil, Egypt, and Thailand) were much larger than were those that did not make such estimates. Sample sizes varied because of resource availability and individual country needs.

Each GATS country used a stratified multistage cluster sampling design in which the probability of a given cluster being selected was proportional to its population

size. Multiple households in selected areas were selected at random. In each selected household, the electronic handheld device that was used for household rostering and data collection used a random number generator to identify one household member to be interviewed. Face-to-face interviews were done in the participant’s local language between Oct 1, 2008, and March 15, 2010, with a handheld electronic data collection device. Interviews were done privately, and in countries where culturally required (eg, Bangladesh, Egypt, India) same-sex interviewers were used. Appendix p 3 describes the years in which data collection occurred, response rates, and the number of respondents for each country’s survey. The fieldwork for each GATS country was completed within about 1–6 months.

Ethics review and approval was undertaken and obtained in collaboration with each country’s implementing agency and Ministry of Health guidelines.

Procedures

15 indicators of tobacco use (panel 1) were constructed from GATS questions (appendix pp 4–5). Of these 15 indicators, many were constructed from equivalent indicators in the General Lifestyle Survey¹⁰ and the Tobacco Use Supplement¹¹ to allow comparisons to be made. In all surveys, quality-assurance procedures were incorporated to improve data quality, as described elsewhere.^{8–11} In GATS, for example, expert committees reviewed questionnaire content and sampling procedures in every country.

See Online for appendix

Panel 1: Indicators of tobacco use in the Global Adult Tobacco Survey (GATS)

- Current smoking: currently smoking any tobacco product on a daily or less than daily basis
- Current daily smoking: currently smoking any tobacco product on a daily basis
- Cigarette smoking: currently smoking cigarettes (manufactured or hand-rolled but not bidis)
- Smoking manufactured cigarettes (including kreteks and papirosy)
- Smoking hand-rolled cigarettes
- Smoking manufactured and hand-rolled cigarettes
- Smoking tobacco products other than cigarettes (eg, cigars, bidis, or waterpipes)
- Daily cigarette smoking: smoking manufactured or hand-rolled cigarettes every day
- Mean number of cigarettes smoked per day among daily cigarette smokers
- Current smokeless tobacco use: using any smokeless tobacco product on a daily or less than daily basis
- Any current tobacco use: currently smoking or using smokeless tobacco
- Ever smoking: ever tried smoking any tobacco product
- Ever daily smoking: ever smoked any tobacco product on a daily basis
- Age of initiation of daily smoking: age when respondent first smoked every day
- Former smoking among ever daily smokers (ie, quit ratio): the percentage of persons who ever smoked daily who no longer smoke

The word “smoking” includes smoking of any tobacco product, such as manufactured cigarettes, hand-rolled cigarettes, kreteks, papirosy, bidis, cigars, pipes, or waterpipes. “Tobacco use” includes smoking and smokeless tobacco use. Some individuals who smoke tobacco also use smokeless tobacco products and some individuals who use smokeless tobacco products also smoke. Further details on the questionnaires used and indicator definitions for GATS, the General Lifestyle Survey,¹⁰ and the Tobacco Use Supplement¹¹ are available in appendix pp 4–5.

	China	India	Bangladesh	Vietnam	Philippines	Thailand	Russia	Ukraine	Poland	Egypt	Turkey	Brazil	Mexico	Uruguay	UK	USA
Men (≥15 years)																
Sample size	6603	33767	4468	4356	4740	10052	6217	4076	3867	10062	4269	18039	6160	2634	6695	75838
Population estimate, millions	544.5 (484.3-604.6)	411.1 (393.6-428.7)	47.4 (44.9-50.0)	31.3 (30.2-32.3)	30.6 (29.2-31.9)	25.6 (24.8-26.3)	50.8 (48.4-53.3)	18.2 (17.6-18.7)	15.4 (14.9-16.0)	25.3 (23.7-26.9)	25.1 (24.3-25.9)	68.5 (65.2-71.8)	32.8 (29.4-36.2)	1.2 (1.1-1.2)	19.5 (18.8-20.2)	111.9 (111.8-112.1)
Current smoking, %	52.9 (50.6-55.2)	24.3 (23.3-25.3)	44.7 (42.5-47.0)	47.4 (45.4-49.4)	47.6 (45.7-49.6)	45.6 (43.8-47.4)	60.2 (58.4-62.0)	50.0 (48.1-52.0)	36.9 (34.9-38.9)	37.6 (36.3-39.0)	47.9 (45.9-50.0)	21.6 (20.8-22.4)	24.8 (23.2-26.6)	30.7 (33.4)	22.8 (21.6-24.2)	24.0 (23.6-24.3)
Daily smoking, %	45.4 (42.8-48.0)	18.3 (17.4-19.3)	40.7 (38.5-42.9)	38.7 (36.9-40.6)	38.2 (36.4-40.2)	39.2 (37.5-41.0)	55.0 (53.1-56.8)	45.5 (43.6-47.4)	33.5 (31.6-35.5)	35.8 (34.5-37.2)	43.8 (41.8-45.9)	18.9 (18.2-19.6)	11.8 (10.7-13.1)	24.8 (22.5-27.3)	NA*	16.4 (16.1-16.8)
Cigarette smoking†, %	52.1 (49.7-54.5)	10.5 (9.8-11.2)	28.3 (26.3-30.4)	39.7 (37.5-41.9)	47.2 (45.3-49.2)	45.4 (43.6-47.2)	59.8 (58.0-61.5)	49.7 (47.8-51.7)	36.7 (34.8-38.7)	31.8 (30.6-33.1)	47.8 (45.7-49.9)	21.4 (20.6-22.1)	24.5 (22.8-26.2)	30.2 (32.8)	21.6 (20.3-22.9)	19.7 (19.4-20.1)
Manufactured only, %	48.2 (45.6-50.7)	8.9 (8.3-9.6)	27.5 (25.5-29.7)	37.8 (35.8-39.9)	44.9 (43.0-46.9)	18.4 (17.3-19.6)	58.1 (56.3-59.9)	47.4 (45.4-49.4)	32.7 (30.9-34.6)	31.6 (30.4-32.9)	43.1 (41.0-45.2)	14.0 (13.4-14.7)	24.0 (22.3-25.7)	16.7 (19.0)	13.3 (14.3)	NA*
Hand-rolled only, %	1.6 (1.1-2.5)	0.9 (0.7-1.1)	0.0	0.6 (0.3-1.0)	0.6 (0.4-1.0)	15.8 (14.6-17.2)	0.1 (0.0-0.3)	0.2 (0.1-0.4)	1.6 (1.2-2.1)	0.1 (0.1-0.3)	2.0 (1.4-2.8)	3.6 (3.3-4.0)	0.0 (0.0-0.0)	5.9 (4.7-7.5)	8.3 (7.5-9.1)	NA*
Both, %	2.3 (1.5-3.5)	0.7 (0.6-0.8)	0.7 (0.4-1.3)	1.3 (0.9-1.9)	1.7 (1.2-2.3)	11.2 (9.9-12.5)	1.2 (0.8-1.7)	2.1 (1.6-2.6)	2.4 (3.3)	0.1 (0.1)	2.7 (3.4)	3.7 (4.1)	0.5 (0.8)	7.5 (9.2)	NA*	NA*
Other smoking‡, %	1.6 (1.0-2.4)	17.1 (16.2-18.1)	22.1 (19.9-24.5)	13.1 (11.5-15.0)	0.5 (0.2-0.9)	0.3 (0.1-0.5)	7.4 (6.3-8.7)	3.9 (3.1-4.9)	1.1 (0.8-1.6)	6.3 (6.9)	4.8 (6.0)	0.7 (0.9)	0.6 (1.1)	1.6 (2.9)	1.3 (1.6)	6.9 (7.1)
Daily cigarette smoking, %	44.6 (41.9-47.2)	6.3 (5.8-6.9)	24.5 (22.6-26.4)	31.0 (29.0-33.1)	38.0 (36.1-39.9)	39.1 (37.4-40.9)	54.7 (52.9-56.5)	45.4 (43.5-47.4)	33.5 (31.6-35.4)	30.6 (29.3-31.8)	43.8 (41.7-45.8)	18.2 (17.5-19.0)	11.7 (10.6-13.0)	24.3 (21.9-26.8)	NA*	15.7 (15.3-16.0)
Mean cigarettes per day§	16.6 (16.0-17.2)	6.1 (5.8-6.5)	8.7 (8.1-9.2)	13.6 (12.7-14.5)	11.3 (10.7-11.8)	12.9 (12.5-13.3)	18.5 (17.9-19.0)	18.1 (17.6-18.7)	18.3 (17.6-19.0)	19.4 (20.1)	19.3 (19.9)	14.7 (15.1)	9.7 (11.0)	17.6 (18.8)	NA*	18.2 (18.0-18.4)
Current smokeless tobacco use, %	0.7 (0.4-1.2)	32.9 (31.6-34.2)	26.4 (24.2-28.6)	0.3 (0.2-0.5)	2.7 (2.1-3.6)	1.3 (1.1-1.7)	1.0 (0.7-1.6)	0.5 (0.2-0.9)	4.1 (3.4-4.8)	NA*	0.6 (0.5-0.8)	0.3 (0.2-0.5)	0.0 (0.0-0.1)	NA*	NA*	3.5 (3.4-3.7)
Any current tobacco use, %	52.9 (50.6-55.2)	47.9 (46.7-49.1)	58.0 (55.9-60.1)	47.6 (45.6-49.6)	49.2 (47.2-51.1)	46.4 (44.6-48.2)	60.6 (58.8-62.4)	50.1 (48.2-52.1)	37.3 (35.3-39.3)	38.1 (36.8-39.4)	47.9 (45.9-50.0)	22.0 (21.3-22.8)	25.0 (23.3-26.7)	30.7 (33.4)	22.8 (21.6-24.2)	26.2 (25.8-26.6)
Women (≥15 years)																
Sample size	6751	35529	5161	5569	4961	10514	5189	4082	3973	10862	4761	21386	7457	2947	7935	98427
Population estimate, millions	524.3 (455.9-592.7)	384.4 (368.3-400.5)	48.0 (45.2-50.7)	33.1 (32.1-34.0)	30.7 (29.3-32.2)	27.0 (26.3-27.8)	61.4 (58.3-64.5)	21.8 (21.1-22.5)	16.9 (16.4-17.4)	24.3 (23.0-25.7)	26.1 (25.3-26.8)	74.5 (70.9-78.0)	36.0 (32.4-39.6)	1.3 (1.4)	22.4 (21.7-23.2)	119.6 (119.5-119.8)
Current smoking, %	2.4 (1.9-3.1)	2.9 (2.6-3.4)	1.5 (1.1-2.1)	1.4 (1.0-2.1)	9.0 (8.0-10.1)	3.1 (2.7-3.6)	21.7 (19.6-23.8)	11.3 (10.0-12.7)	24.4 (22.8-26.0)	0.5 (0.3-0.8)	15.2 (14.0-16.5)	13.1 (12.6-13.7)	7.8 (6.7-9.1)	19.8 (21.6)	20.6 (19.5-21.8)	16.2 (15.9-16.5)
Daily smoking, %	2.0 (1.5-2.6)	2.4 (2.1-2.8)	1.3 (0.9-1.9)	1.2 (0.8-1.8)	6.9 (6.0-7.8)	2.4 (2.0-2.9)	16.3 (14.5-18.2)	8.9 (7.7-10.2)	21.0 (19.6-22.5)	0.5 (0.3-0.7)	11.6 (10.5-12.8)	11.5 (11.0-12.1)	3.7 (3.0-4.6)	16.4 (14.8-18.1)	NA*	12.8 (12.6-13.1)
Cigarette smoking†, %	2.3 (1.8-3.0)	0.9 (0.7-1.1)	0.2 (0.1-0.5)	1.2 (0.8-1.8)	8.8 (7.8-9.9)	2.8 (2.4-3.3)	21.4 (19.4-23.6)	11.1 (9.8-12.5)	24.2 (22.6-25.8)	0.2 (0.1-0.4)	15.1 (13.9-16.4)	12.9 (12.3-13.4)	7.5 (6.4-8.8)	19.8 (21.6)	20.6 (19.4-21.8)	15.8 (15.5-16.1)
Manufactured only, %	1.8 (1.3-2.4)	0.1 (0.1-0.2)	0.2 (0.1-0.4)	0.8 (0.5-1.2)	7.1 (6.2-8.2)	1.0 (1.2)	21.0 (19.0-23.2)	10.9 (9.7-12.3)	22.1 (20.6-23.6)	0.2 (0.1-0.4)	14.5 (13.3-15.7)	9.8 (9.3-10.4)	7.3 (6.3-8.6)	16.5 (18.2)	16.5 (15.5-17.5)	NA*
Hand-rolled only, %	0.4 (0.2-0.6)	0.3 (0.2-0.5)	0.1 (0.0-0.3)	0.2 (0.1-0.4)	1.3 (0.9-1.8)	1.7 (1.4-2.1)	0.0	0.0	1.3 (0.8-1.9)	0.0	0.2 (0.1-0.5)	1.7 (2.0)	0.0 (0.0-0.0)	1.2 (1.9)	4.1 (3.6-4.7)	NA*
Both, %	0.2 (0.1-0.4)	0.4 (0.3-0.6)	0.0	0.2 (0.0-0.9)	0.3 (0.2-0.6)	0.1 (0.2)	0.3 (0.6)	0.1 (0.4)	0.9 (1.3)	0.0 (0.1)	0.4 (0.7)	1.3 (1.5)	0.2 (0.3)	2.1 (2.9)	NA*	NA*

(Continues on next page)

	China	India	Bangladesh	Vietnam	Philippines	Thailand	Russia	Ukraine	Poland	Egypt	Turkey	Brazil	Mexico	Uruguay	UK	USA
(Continued from previous page)																
Other smoking‡, %	0.1 (0.0-0.4)	2.4 (2.0-2.8)	1.3 (0.9-1.9)	0.2 (0.1-0.5)	0.3 (0.2-0.5)	0.3 (0.1-0.7)	3.6 (2.7-4.8)	1.3 (0.9-1.8)	0.4 (0.2-0.7)	0.3 (0.2-0.6)	0.8 (0.5-1.3)	0.7 (0.5-0.8)	0.2 (0.1-0.4)	0.2 (0.1-0.5)	0.0 (0.0-0.1)	0.8 (0.8-0.9)
Daily cigarette smoking, %	1.9 (1.4-2.5)	0.6 (0.4-0.8)	0.2 (0.1-0.5)	1.0 (0.6-1.5)	6.7 (5.9-7.7)	2.2 (1.9-2.6)	16.3 (14.5-18.2)	8.9 (7.7-10.2)	20.9 (19.5-22.4)	0.2 (0.1-0.3)	11.6 (10.5-12.8)	11.0 (10.5-11.5)	3.7 (2.9-4.5)	16.4 (14.8-18.1)	NA*	12.7 (12.5-13.0)
Mean cigarettes per day§	12.8 (11.7-14.0)	7.0 (5.5-8.5)	NA¶	10.9 (9.4-12.4)	6.9 (6.1-7.8)	8.6 (7.3-9.8)	12.7 (11.8-13.5)	11.8 (10.9-12.6)	15.5 (14.9-16.1)	NA¶	12.2 (11.2-13.1)	12.4 (12.0-12.9)	8.4 (6.0-10.7)	12.5 (11.5-13.5)	NA*	15.2 (15.0-15.3)
Current smokeless tobacco use, %	0.0 (0.0-0.1)	18.4 (17.4-19.5)	27.9 (25.9-30.0)	2.3 (1.7-3.0)	1.2 (0.8-1.6)	6.3 (5.5-7.2)	0.2 (0.1-0.4)	0.0 (0.0-0.1)	0.1 (0.0-0.3)	0.3 (0.2-0.4)	NA*	0.3 (0.2-0.4)	0.3 (0.2-0.6)	0.0	NA*	0.2 (0.2-0.2)
Any current tobacco use, %	2.4 (1.9-3.1)	20.3 (19.2-21.3)	28.7 (26.7-30.8)	3.6 (2.9-4.5)	10.0 (8.9-11.1)	9.1 (8.2-10.2)	21.7 (19.7-23.9)	11.3 (10.0-12.7)	24.4 (22.8-26.0)	0.6 (0.4-0.9)	15.2 (14.0-16.5)	13.3 (12.8-13.9)	7.9 (6.8-9.2)	19.8 (18.1-21.6)	20.6 (19.5-21.8)	16.3 (16.0-16.6)
Overall (±15 years)																
Sample size	13 354	69 296	9629	9925	9701	20 566	11 406	8 158	7 840	20 924	9 030	39 425	13 617	5 581	14 630	174 265
Population estimate, millions	1068.8 (946.7-1190.8)	795.5 (762.4-828.7)	95.4 (90.4-100.4)	64.3 (63.2-65.5)	61.3 (58.6-63.9)	52.6 (51.3-54.0)	112.2 (106.9-117.6)	40.0 (38.8-41.2)	32.3 (31.8-32.9)	49.7 (46.8-52.5)	51.2 (49.8-52.5)	143.0 (136.1-149.9)	68.8 (61.9-75.6)	2.5 (2.4-2.5)	41.9 (40.6-43.3)	231.6 (231.7)
Current smoking, %	28.1 (26.7-29.7)	14.0 (13.4-14.6)	23.0 (21.9-24.2)	23.8 (22.7-24.9)	28.2 (27.0-29.5)	23.7 (22.8-24.7)	39.1 (37.8-40.5)	28.9 (27.7-30.1)	30.3 (29.0-31.7)	19.4 (18.8-20.1)	31.2 (30.0-32.6)	17.2 (16.7-17.7)	15.9 (14.8-17.1)	25.0 (23.3-26.6)	21.7 (20.7-22.7)	19.9 (19.7-20.2)
Daily smoking, %	24.1 (22.6-25.7)	10.7 (10.2-11.2)	20.9 (19.8-22.0)	19.5 (18.4-20.5)	22.5 (21.4-23.7)	20.3 (19.4-21.2)	33.8 (32.5-35.1)	25.5 (24.4-26.7)	27.0 (25.8-28.2)	18.5 (17.8-19.2)	27.4 (26.2-28.7)	15.1 (14.6-15.5)	7.6 (6.8-8.3)	20.4 (19.1-21.8)	NA*	14.6 (14.4-14.8)
Cigarette smoking‡, %	27.7 (26.2-29.2)	5.8 (5.5-6.2)	14.2 (13.2-15.2)	19.9 (18.7-21.1)	27.9 (26.8-29.2)	23.5 (22.6-24.5)	38.8 (37.4-40.2)	28.6 (27.5-29.8)	30.2 (28.8-31.5)	16.3 (15.7-17.0)	31.1 (29.9-32.5)	16.9 (16.5-17.4)	15.6 (14.5-16.8)	24.7 (23.1-26.4)	21.0 (20.1-22.0)	17.7 (17.5-17.9)
Manufactured only, %	25.4 (23.9-27.0)	4.7 (4.4-5.0)	13.8 (12.8-14.8)	18.8 (17.7-19.9)	26.0 (24.8-27.2)	9.5 (8.9-10.1)	37.8 (36.5-39.2)	27.5 (26.3-28.7)	27.1 (25.9-28.4)	16.2 (15.6-16.9)	28.5 (27.3-29.8)	11.8 (11.4-12.3)	15.3 (14.1-16.5)	16.6 (15.2-18.1)	15.0 (14.2-15.8)	NA*
Hand-rolled only, %	1.0 (0.7-1.5)	0.6 (0.5-0.8)	0.0 (0.0-0.2)	0.4 (0.3-0.6)	0.9 (0.7-1.3)	8.6 (7.9-9.3)	0.0 (0.0-0.1)	0.1 (0.1-0.2)	1.4 (1.1-1.8)	0.1 (0.0-0.1)	1.1 (0.7-1.5)	2.6 (2.4-2.9)	0.0 (0.0-0.0)	3.4 (2.8-4.3)	6.0 (5.5-6.6)	NA*
Both, %	1.3 (0.8-1.9)	0.5 (0.5-0.7)	0.4 (0.2-0.6)	0.7 (0.5-1.2)	1.0 (0.7-1.3)	5.5 (4.9-6.2)	0.7 (0.5-1.0)	1.0 (0.8-1.3)	1.6 (1.2-2.1)	0.0 (0.0-0.1)	1.5 (1.2-1.9)	2.5 (2.2-2.7)	0.3 (0.2-0.5)	4.7 (3.9-5.7)	NA*	NA*
Other smoking‡, %	0.9 (0.6-1.3)	10.0 (9.5-10.6)	11.7 (10.5-12.9)	6.5 (5.7-7.4)	0.4 (0.2-0.6)	0.3 (0.1-0.5)	5.3 (4.4-6.4)	2.5 (2.0-3.0)	0.7 (0.5-1.0)	3.3 (3.0-3.7)	2.8 (2.2-3.2)	0.7 (0.6-0.8)	0.4 (0.2-0.6)	0.9 (0.5-1.5)	0.6 (0.5-0.8)	3.8 (3.6-3.9)
Daily cigarette smoking, %	23.6 (22.1-25.2)	3.5 (3.3-3.9)	12.3 (11.4-13.2)	15.6 (14.5-16.7)	22.3 (21.2-23.4)	20.1 (19.2-21.0)	33.7 (32.4-35.0)	25.5 (24.3-26.6)	26.9 (25.7-28.2)	15.7 (15.0-16.3)	27.4 (26.2-28.6)	14.5 (14.0-14.9)	7.5 (6.8-8.3)	20.1 (18.8-21.5)	NA*	14.1 (13.9-14.4)
Mean cigarettes per day§	16.1 (15.6-16.7)	2.1 (1.9-2.3)	5.1 (4.6-5.6)	10.9 (10.0-11.7)	10.5 (10.0-11.0)	12.5 (12.1-12.9)	16.9 (16.4-17.4)	16.9 (16.4-17.4)	17.1 (16.6-17.6)	16.4 (15.7-17.1)	17.7 (17.1-18.3)	13.3 (12.9-13.6)	9.3 (8.1-10.6)	15.2 (14.3-16.1)	NA*	16.8 (16.6-16.9)
Current smokeless tobacco use, %	0.4 (0.2-0.7)	25.9 (24.9-26.9)	27.2 (25.5-28.9)	1.3 (1.0-1.7)	1.9 (1.5-2.5)	3.9 (3.4-4.4)	0.6 (0.4-0.9)	0.2 (0.1-0.4)	0.5 (0.4-0.8)	2.2 (1.9-2.6)	0.0	0.4 (0.4-0.5)	0.3 (0.2-0.5)	0.0 (0.0-0.0)	NA*	1.8 (1.7-1.9)
Any current tobacco use, %	28.1 (26.7-29.7)	34.6 (33.6-35.5)	43.3 (41.7-45.0)	25.0 (23.8-26.2)	29.5 (28.3-30.8)	27.2 (26.2-28.3)	39.3 (38.0-40.8)	28.9 (27.8-30.1)	30.5 (29.2-31.9)	19.7 (19.0-20.4)	31.2 (30.0-32.6)	17.5 (17.0-18.0)	16.0 (14.9-17.3)	25.0 (23.3-26.6)	21.7 (20.7-22.7)	21.1 (20.9-21.3)

Data are n, n (95% CI), or % (95% CI). Apart from the mean number of cigarettes smoked per day, estimates are among all men, all women, or the total population (as relevant) in each country. Definitions for these indicators differ in the General Lifestyle Survey (UK)¹⁰ and the Tobacco Use Supplement to the Current Population Survey (USA)¹¹ compared with those used in the 14 GATS countries. See Methods and appendix for details. Data from the 2008-10 GATS,^{9,10} 2008 General Lifestyle Survey (UK),¹⁰ and the 2006-07 Tobacco Use Supplement to the Current Population Survey (USA).¹¹ NA=not available. GATS=Global Adult Tobacco Survey. *Country did not collect data for this variable. †Cigarette smoking includes manufactured and hand-rolled cigarettes, but not bidis; estimates for Brazil and Philippines include kreteks; cigarette smoking estimate in Russia includes cardboard tube-tipped cigarettes (papirosy). ‡Eg, bidi, shisha, cigar, or pipe. §Among daily cigarette smokers. ¶Estimate not reported because sample size was <25 individuals.

Table 1: Patterns of tobacco use, by sex, in the UK, USA, and 14 GATS countries

Statistical analysis

The surveys in this study used complex sample designs that involved clustering of households.⁸⁻¹¹ We calculated sampling weights to account for differential probabilities of selection and participation. We calculated all point estimates and 95% CIs from weighted data with SPSS version 18.0, which estimated variances while accounting for the clustered sample designs. Estimates for eight indicators were also age-standardised via the direct method, and assuming the WHO world standard population (aged ≥15 years).¹² Estimates based on a sample size of fewer than 25 individuals were not reported due to instability. We used Pearson product moment correlations to compare the mean number of cigarettes smoked each day with daily cigarette smoking prevalence across countries.

Role of the funding source

Bloomberg Philanthropies collaborated with the GATS Collaborative Group (see appendix p 1) on the design of GATS samples and questionnaires. Study sponsors had no role in study design, data collection, data analysis, or data interpretation. Bloomberg Philanthropies made comments on a previous draft of the report. GAG had final decision authority on the content of the report. GAG

and SAM had full access to GATS and Tobacco Use Supplement data. MJ had full access to the General Lifestyle Survey data. All authors share final responsibility for the decision to submit for publication.

Results

Table 1 shows sex-specific and country-specific patterns of tobacco use, and sample sizes are shown in appendix p 6. Prevalence of smoking any tobacco product was generally much higher for men than women in every GATS country (figure, appendix p 7). In men, the prevalence of current smoking ranged from 21.6% (95% CI 20.8–22.4) in Brazil to 60.2% (58.4–62.0) in Russia. In women, current smoking prevalence ranged from 0.5% (0.3–0.8) in Egypt to 24.4% (22.8–26.0) in Poland. In the UK, about the same proportion of men (22.8%, 21.6–24.2) and women (20.6%, 19.5–21.8) smoked; in the USA, men were more likely to smoke (24.0%, 23.6–24.3) than were women (16.2%, 15.9–16.5). For GATS countries, the male:female prevalence ratio for smoking was highest in Egypt (75) and Asian countries such as Vietnam (33) and China (22) and was lowest in Poland (1.5) and Uruguay (1.6).

In GATS countries, most current smokers were daily smokers (75.0–95.2%), apart from in Mexico, where




Figure: Proportion of adults ages 15 years or older who currently smoke cigarettes and other tobacco products and number of current tobacco smokers (in millions), by sex, for the UK, USA, and 14 GATS countries
GATS=Global Adult Tobacco Survey.

fewer than half smoked every day (appendix pp 8–9). With the exception of India, most smokers smoked cigarettes, particularly manufactured cigarettes (figure, appendix pp 9–10). For men, smoking of bidis was common in Bangladesh (21.4%, 95% CI 19.2–23.7) and India (16.1%, 15.2–17.0), whereas use of waterpipes was relatively high

in Vietnam (13.0%, 11.4–14.9), Egypt (6.2%, 5.6–6.9), Russia (4.4%, 3.6–5.5), Turkey (4.0%, 3.0–5.1), and Ukraine (3.2%, 2.4–4.1; appendix p 11). For women in Russia, use of waterpipes was 3.2% (2.4–4.3).

Intensity of smoking in male daily cigarette smokers ranged from 6.1 cigarettes per day (95% CI 5.8–6.5) in

	China	India	Bangladesh	Vietnam	Philippines	Thailand	Russia	Ukraine	Poland	Egypt	Turkey	Brazil	Mexico	Uruguay	UK	USA
Men (≥15 years)																
Sample size	6603	33767	4468	4356	4740	10052	6217	4076	3867	10062	4269	18039	6160	2634	6695	75838
Population estimate, millions	544.5 (484.3–604.6)	411.1 (393.6–428.7)	47.4 (44.9–50.0)	31.3 (30.2–32.3)	30.6 (29.2–31.9)	25.6 (24.8–26.3)	50.8 (48.4–53.3)	18.2 (17.6–18.7)	15.4 (14.9–16.0)	25.3 (23.7–26.9)	25.1 (24.3–25.9)	68.5 (65.2–71.8)	32.8 (29.4–36.2)	1.2 (1.1–1.2)	19.5 (18.8–20.2)	111.9 (111.8–112.1)
Age (years)																
15–24	33.6 (28.0–39.6)	9.7 (8.5–11.0)	24.0 (20.4–28.0)	26.1 (22.4–30.2)	38.5 (34.8–42.3)	37.4 (32.5–42.6)	52.5 (48.6–56.4)	45.1 (40.0–50.4)	28.4 (23.6–33.7)	21.7 (19.3–24.3)	39.6 (34.7–44.7)	14.8 (13.5–16.2)	26.7 (23.6–30.1)	28.9 (23.4–35.0)	24.2 (20.4–28.4)	20.7 (19.8–21.7)
25–34	53.0 (48.0–57.9)	22.4 (20.7–24.3)	48.8 (44.4–53.2)	52.9 (48.8–56.9)	58.0 (54.0–61.9)	49.8 (46.2–53.4)	69.2 (65.5–72.7)	60.7 (56.4–64.9)	42.6 (38.7–46.7)	44.0 (41.5–46.6)	58.2 (54.1–62.1)	20.2 (18.8–21.7)	28.0 (25.0–31.1)	39.8 (33.6–46.3)	30.4 (26.8–34.4)	28.7 (27.8–29.5)
35–44	63.7 (59.5–67.6)	32.0 (30.1–33.9)	57.9 (54.1–61.7)	59.9 (56.1–63.6)	52.9 (49.3–56.5)	52.7 (49.6–55.9)	67.2 (63.0–71.2)	60.2 (55.6–64.7)	41.5 (37.3–45.8)	47.9 (45.3–50.5)	58.2 (54.3–62.1)	25.1 (23.4–26.8)	24.9 (21.9–28.2)	29.2 (24.1–34.8)	25.2 (22.4–28.2)	26.4 (25.6–27.2)
45–54	66.3 (62.8–69.7)	38.4 (36.0–40.8)	61.6 (56.3–66.6)	61.5 (57.3–65.6)	48.4 (43.7–53.1)	46.4 (43.5–49.4)	65.1 (61.5–68.6)	57.4 (53.1–61.5)	47.7 (43.2–52.3)	50.0 (46.9–53.1)	50.6 (46.3–54.9)	29.0 (27.1–31.1)	25.1 (21.4–29.3)	38.4 (32.1–45.1)	25.5 (22.8–28.5)	28.5 (27.6–29.4)
55–64	58.9 (53.8–63.8)	36.0 (33.2–38.9)	52.6 (45.9–59.2)	55.7 (50.0–61.4)	46.2 (40.5–52.0)	43.6 (40.1–47.1)	58.2 (53.9–62.4)	43.4 (38.6–48.3)	35.0 (30.4–39.9)	45.1 (41.5–48.8)	39.9 (34.9–45.2)	26.6 (24.2–29.2)	20.6 (16.9–24.8)	30.0 (23.6–37.3)	22.3 (20.0–24.8)	23.9 (23.1–24.8)
≥65	40.2 (35.8–44.9)	31.0 (28.3–33.8)	39.1 (32.7–45.9)	33.3 (28.5–38.4)	36.6 (30.5–43.1)	37.7 (34.2–41.4)	40.7 (35.6–46.1)	25.3 (21.8–29.1)	20.4 (16.3–25.3)	34.9 (30.7–39.5)	20.5 (16.8–24.8)	17.3 (15.4–19.3)	13.1 (10.7–15.9)	13.2 (9.8–17.5)	12.6 (10.9–14.4)	12.6 (12.0–13.3)
Women (≥15 years)																
Sample size	6751	35529	5161	5569	4961	10514	5189	4082	3973	10862	4761	21386	7457	2947	7935	98427
Population estimate, millions	524.3 (455.9–592.7)	384.4 (368.3–400.5)	48.0 (45.2–50.7)	33.1 (32.1–34.0)	30.7 (29.3–32.2)	27.0 (26.3–27.8)	61.4 (58.3–64.5)	21.8 (21.1–22.5)	16.9 (16.4–17.4)	24.3 (23.0–25.7)	26.1 (25.3–26.8)	74.5 (70.9–78.0)	36.0 (32.4–39.6)	1.3 (1.2–1.4)	22.4 (21.7–23.2)	119.6 (119.5–119.8)
Age (years)																
15–24	0.7 (0.2–1.9)	0.3 (0.2–0.6)	0.4 (0.1–1.0)	0.3 (0.0–1.4)	3.0 (2.0–4.7)	1.4 (0.9–2.3)	32.6 (27.7–38.0)	15.4 (11.1–20.8)	20.2 (16.3–24.7)	0.2 (0.1–0.6)	11.6 (9.1–14.6)	6.4 (5.6–7.4)	7.5 (5.8–9.6)	20.2 (15.6–25.8)	28.8 (24.8–33.2)	15.0 (14.2–15.7)
25–34	0.3 (0.1–0.7)	1.3 (0.9–1.8)	0.7 (0.3–1.7)	0.4 (0.2–1.0)	6.7 (5.0–8.9)	1.5 (1.0–2.1)	32.1 (28.1–36.4)	23.4 (19.4–28.0)	25.4 (21.9–29.2)	0.2 (0.1–0.5)	22.6 (20.0–25.4)	12.6 (11.6–13.8)	8.9 (7.1–11.0)	29.3 (24.5–34.7)	25.3 (22.4–28.5)	19.1 (18.3–19.8)
35–44	2.4 (1.4–3.9)	3.2 (2.5–4.0)	1.5 (0.7–3.2)	1.4 (0.7–2.8)	8.7 (6.8–11.2)	3.0 (2.1–4.1)	30.6 (25.9–35.7)	16.4 (13.0–20.6)	30.9 (26.8–35.4)	0.6 (0.4–1.2)	20.1 (17.1–23.5)	16.5 (15.1–17.9)	7.7 (5.9–9.9)	22.6 (18.3–27.7)	23.7 (21.3–26.2)	19.4 (18.7–20.1)
45–54	3.5 (2.5–4.8)	4.3 (3.4–5.4)	1.5 (0.8–2.9)	2.8 (1.8–4.1)	15.3 (12.1–19.1)	4.0 (3.1–5.2)	22.1 (18.2–26.6)	11.2 (8.5–14.6)	38.1 (33.6–42.8)	1.2 (0.6–2.3)	14.7 (11.8–18.2)	19.9 (18.2–21.6)	10.7 (8.4–13.5)	26.1 (20.4–32.7)	22.2 (19.7–24.9)	20.2 (19.5–20.9)
55–64	2.8 (1.8–4.4)	7.7 (5.7–10.4)	4.6 (2.7–7.6)	3.1 (1.7–5.4)	15.1 (11.1–20.1)	4.9 (3.7–6.6)	12.6 (9.7–16.2)	3.7 (2.3–6.0)	28.5 (24.4–32.9)	0.7 (0.3–1.7)	10.7 (7.7–14.7)	15.0 (13.3–16.9)	6.0 (3.8–9.3)	19.4 (14.8–25.1)	17.6 (15.6–19.7)	15.5 (14.9–16.1)
≥65	6.7 (4.8–9.2)	9.9 (7.9–12.4)	6.6 (3.5–12.2)	3.0 (1.6–5.4)	21.0 (16.3–26.7)	5.6 (4.2–7.4)	2.9 (1.7–4.9)	0.0 (0.0–0.0)	6.6 (4.6–9.6)	1.4 (0.7–3.1)	2.4 (1.3–4.3)	9.3 (8.1–10.7)	3.0 (1.8–5.0)	5.2 (3.8–7.1)	11.4 (10.0–13.0)	7.4 (7.0–7.9)

Data are n, n (95% CI) or % (95% CI). GATS=Global Adult Tobacco Survey. In GATS, current smokers are individuals who smoke tobacco daily or less than daily. In the General Lifestyle Survey, current smokers are men who smoke cigarettes, cigars, or pipes and women who smoke cigarettes or cigars. In the Tobacco Use Supplement to the Current Population Survey, current smokers include individuals who have ever smoked at least 100 cigarettes in their lifetimes and who smoke cigarettes every day or on some days, and individuals who smoke cigars or pipes on every day or on some days. Data from the 2008–10 GATS,^{8,9} 2008 General Lifestyle Survey (UK),¹⁰ and the 2006–07 Tobacco Use Supplement to the Current Population Survey (USA).¹¹

Table 2: Current smoking prevalence (%), by sex and age, in the UK, USA, and 14 GATS countries

India to 19.4 cigarettes per day (18.7–20.1) in Egypt (table 1, appendix p 12). In female daily cigarette smokers, the range was 6.9 cigarettes per day (6.1–7.8) in the Philippines to 15.5 cigarettes per day (14.9–16.1) in Poland. Among all countries, the mean number of cigarettes smoked each day was directly correlated with the prevalence of daily cigarette smoking ($r=0.672$ and $p=0.009$ in men; $r=0.714$ and $p=0.009$ in women).

In most countries, prevalence estimates for any current tobacco use were much the same as those for current smoking. However, these two estimates differed in India and Bangladesh, where the use of smokeless tobacco was common (table 1, appendix p 13). In men, prevalence of tobacco use was highest in Russia at 60.6% (58.8–62.4) and second highest in Bangladesh at 58.0% (55.9–60.1); in women, prevalence of tobacco use in Bangladesh

	China	India	Bangladesh	Vietnam	Philippines	Thailand	Russia	Ukraine	Poland	Egypt	Turkey	Brazil	Mexico	Uruguay	UK*	USA†
Men																
Ever smokers (≥15 years)	62.8 (60.4–65.1)	29.3 (28.2–30.4)	55.5 (53.2–57.8)	66.5 (64.5–68.5)	64.4 (62.3–66.4)	67.7 (65.8–69.6)	78.3 (76.8–79.8)	73.1 (71.4–74.8)	63.4 (61.5–65.4)	46.1 (44.6–47.6)	70.0 (68.1–71.9)	43.0 (42.1–43.9)	45.9 (43.9–47.9)	58.5 (55.9–61.1)	63.2 (61.7–64.7)	NA‡
Ever daily smokers (≥15 years)	52.2 (49.5–54.9)	21.1 (20.1–22.1)	49.1 (46.9–51.3)	51.4 (49.5–53.4)	49.3 (47.3–51.3)	56.0 (54.0–57.9)	68.3 (66.5–70.0)	62.4 (60.4–64.3)	55.4 (53.3–57.4)	43.1 (41.7–44.6)	61.0 (59.0–63.0)	36.1 (35.3–37.0)	19.4 (18.0–20.9)	45.3 (42.8–47.9)	51.4 (49.9–52.8)	41.6 (41.2–42.0)
Mean age of initiation by age group, years																
25–34	20.2 (19.6–20.8)	18.8 (18.4–19.3)	17.9 (17.5–18.3)	19.4 (19.0–19.9)	17.9 (17.5–18.3)	18.0 (17.7–18.4)	17.0 (16.7–17.3)	17.1 (16.8–17.5)	17.7 (17.4–18.0)	17.6 (17.4–17.9)	17.0 (16.6–17.3)	17.3 (17.0–17.5)	16.7 (16.0–17.4)	16.3 (15.8–16.8)	16.4 (16.0–16.8)	17.2 (17.3)
35–44	20.6 (20.3–20.9)	21.1 (20.6–21.5)	19.0 (18.4–19.7)	19.4 (19.0–19.8)	18.2 (17.8–18.6)	18.7 (18.3–19.0)	17.8 (17.5–18.1)	17.7 (17.3–18.1)	18.5 (18.2–18.8)	18.4 (18.1–18.8)	16.6 (16.2–17.0)	17.5 (17.3–17.8)	17.1 (16.5–17.8)	17.4 (16.8–18.1)	17.1 (16.7–17.5)	17.7 (17.8)
45–54	21.7 (21.2–22.3)	22.1 (21.6–22.6)	19.1 (18.5–19.8)	20.3 (19.7–20.9)	19.1 (18.5–19.6)	18.6 (18.3–18.9)	17.9 (17.6–18.3)	18.3 (17.9–18.6)	18.6 (18.1–19.2)	18.9 (18.4–19.4)	17.4 (16.8–17.9)	17.5 (17.2–17.9)	17.1 (16.3–17.8)	17.3 (16.6–18.0)	16.9 (16.3–17.5)	17.6 (17.7)
55–64	22.3 (21.6–22.9)	23.4 (22.3–24.6)	18.7 (17.9–19.5)	20.7 (20.0–21.4)	18.1 (17.3–19.0)	18.4 (18.0–18.9)	18.2 (17.6–18.8)	18.2 (17.7–18.7)	18.3 (17.8–18.7)	19.1 (18.6–19.7)	18.1 (17.4–18.8)	17.8 (17.3–18.2)	18.5 (17.2–19.7)	17.0 (16.1–17.9)	16.3 (15.9–16.6)	17.4 (17.2)
≥65	23.9 (23.0–24.9)	23.7 (22.8–24.7)	19.9 (17.9–21.9)	22.9 (21.3–24.4)	19.7 (18.3–21.0)	19.3 (18.7–19.9)	18.1 (17.4–18.7)	16.8 (16.1–17.5)	19.0 (18.5–19.4)	19.3 (18.5–20.2)	19.6 (18.5–20.8)	17.2 (16.7–17.7)	17.8 (16.5–19.0)	17.3 (16.4–18.1)	16.9 (16.5–17.2)	17.3 (17.5)
Women																
Ever smokers (≥15 years)	3.1 (2.5–3.9)	3.7 (3.2–4.2)	2.7 (2.0–3.6)	2.5 (1.9–3.2)	14.8 (13.6–16.1)	5.6 (5.0–6.4)	31.9 (29.5–34.6)	19.8 (18.1–21.5)	41.5 (39.5–43.5)	0.7 (0.5–1.0)	25.2 (23.5–26.9)	28.3 (27.6–29.1)	16.6 (15.1–18.3)	40.2 (38.0–42.5)	52.0 (50.6–53.5)	NA‡
Ever daily smokers (≥15 years)	2.4 (1.9–3.1)	3.0 (2.6–3.4)	2.3 (1.7–3.2)	1.7 (1.3–2.4)	9.4 (8.4–10.4)	3.8 (3.3–4.4)	20.0 (18.0–22.2)	12.1 (10.7–13.6)	32.3 (30.6–34.1)	0.6 (0.4–0.9)	15.7 (14.4–17.0)	22.7 (22.0–23.4)	6.1 (5.3–7.1)	42.5 (27.2–31.2)	42.3 (40.9–43.7)	32.2 (31.9–32.6)
Mean age of initiation by age group, years																
25–34	NA§	17.5 (15.7–19.4)	NA§	NA§	20.1 (18.7–21.5)	19.1 (18.2–20.0)	17.5 (17.1–18.0)	19.0 (18.4–19.6)	18.2 (17.8–18.6)	NA§	18.2 (17.6–18.7)	17.6 (17.2–17.9)	17.9 (17.0–18.7)	17.1 (16.5–17.7)	16.1 (15.8–16.4)	17.2 (17.3)
35–44	26.5 (24.4–28.5)	23.3 (21.3–25.3)	NA§	NA§	26.0 (23.9–28.1)	20.8 (19.1–22.5)	20.7 (19.9–21.6)	21.3 (20.4–22.2)	19.6 (19.0–20.2)	NA§	19.5 (18.7–20.4)	18.2 (17.7–18.6)	20.6 (18.9–22.3)	18.4 (17.5–19.2)	16.5 (16.1–16.9)	17.6 (17.7)
45–54	27.8 (24.1–31.5)	27.6 (24.7–30.5)	NA§	25.9 (22.4–29.4)	26.4 (24.2–28.6)	24.0 (21.3–26.6)	23.0 (21.5–24.6)	26.7 (24.5–28.9)	20.5 (20.0–21.0)	NA§	20.5 (19.5–21.5)	18.6 (18.2–19.1)	21.4 (19.7–23.1)	18.5 (17.6–19.4)	17.3 (16.7–18.0)	18.2 (18.3)
55–64	25.6 (21.9–29.3)	28.2 (24.6–31.9)	24.2 (18.6–29.8)	NA§	25.7 (22.5–28.9)	25.6 (23.2–28.0)	24.1 (21.9–26.2)	29.0 (25.6–32.3)	20.7 (20.1–21.4)	NA§	26.3 (23.8–28.9)	20.2 (19.5–20.9)	23.7 (21.7–25.6)	20.3 (18.0–22.7)	17.6 (17.1–18.1)	19.2 (19.0–19.3)
≥65	30.4 (26.3–34.5)	30.2 (26.9–33.5)	30.1 (18.1–42.0)	23.2 (18.3–28.2)	27.1 (24.2–30.0)	23.4 (21.1–25.7)	23.3 (19.0–27.7)	NA§	25.5 (22.1–28.9)	NA§	31.2 (25.9–36.4)	20.8 (19.9–21.8)	22.5 (19.4–25.6)	24.3 (22.6–26.1)	20.7 (19.5–21.9)	20.2 (20.0)

Data are % (95% CI) or n (95% CI). Data from the 2008–10 GATS,^{8,9} 2008 General Lifestyle Survey (UK),¹⁰ and the 2006–07 Tobacco Use Supplement to the Current Population Survey (USA).¹¹ Estimates for individuals aged 15–24 years are not included here because daily smoking rates have not stabilised by this age. NA=not available. GATS=Global Adult Tobacco Survey. *UK study¹⁰ measured ever regular (not daily) smoking of cigarettes, cigars, or pipes and age of initiation of regular cigarette smoking. †US study¹¹ measured ever having smoked at least 100 lifetime cigarettes and age of initiation of regular cigarette smoking. See methods and appendix for details. ‡Country did not collect data for this variable. §Estimate not reported because sample size was <25 individuals.

Table 3: Prevalence of ever smoking and mean age of initiation of daily smoking among ever daily smokers, by sex and age in the UK, USA, and 14 GATS countries, and similar estimates for ever regular smokers in the UK and USA

(28.7%, 26.7–30.8) exceeded that noted in Poland (24.4%, 22.8–26.0; table 1, appendix p 14). The percentage of men who used both smoked and smokeless tobacco products was highest in Bangladesh (13.0%, 11.6–14.6), India (9.3%, 8.7–9.9), and Egypt (3.6%, 3.0–4.3; appendix p 15).

Weighted estimates of the number of individuals who smoked or used various tobacco products in each country are presented in appendix pp 16–21. In the 14 GATS countries, UK, and USA, we estimated that there were 852 million tobacco users, made up of 661 million

	China	India	Bangladesh	Vietnam	Philippines	Thailand	Russia	Ukraine	Poland	Egypt	Turkey	Brazil	Mexico	Uruguay	UK	USA
Men (≥15 years)																
Sample size	4048	9748	2457	2594	2656	6207	4497	2759	2282	4884	2854	6938	1424	1345	3658	34973
Population estimate (ever daily smokers), millions	297.0 (264.2–329.9)	92.5 (86.9–98.0)	24.1 (22.5–25.6)	17.0 (16.2–17.8)	16.2 (15.4–17.0)	15.1 (14.5–15.6)	36.0 (34.1–37.9)	11.7 (11.3–12.2)	8.8 (8.4–9.2)	11.1 (10.4–11.8)	15.8 (15.2–16.5)	25.5 (24.2–26.7)	7.9 (6.8–8.9)	0.6 (0.5–0.6)	10.4 (9.9–10.8)	46.7 (46.2–47.1)
Former smoking in ever daily smokers, %	12.6 (10.8–14.6)	12.1 (10.9–13.5)	16.6 (14.5–19.1)	23.3 (21.2–25.5)	20.9 (19.0–22.8)	28.4 (26.6–30.4)	18.8 (17.2–20.5)	26.1 (24.2–28.1)	38.3 (35.7–41.1)	16.5 (15.1–18.0)	27.2 (25.3–29.2)	46.4 (44.9–47.8)	31.6 (28.3–35.0)	42.8 (39.1–46.5)	57.1 (55.1–59.0)	48.7 (48.1–49.2)
Age (years)																
15–24	2.4 (0.9–6.4)	7.4 (4.4–12.4)	7.6 (3.2–16.7)	6.5 (3.0–13.4)	5.5 (3.4–8.9)	5.7 (3.2–10.0)	7.8 (5.0–11.8)	15.5 (10.8–21.7)	13.6 (8.4–21.2)	7.9 (5.2–11.6)	6.6 (3.4–12.4)	14.0 (11.1–17.6)	8.5 (4.7–14.9)	13.1 (6.7–24.0)	20.9 (14.9–28.7)	19.4 (17.4–21.5)
25–34	3.3 (1.7–6.1)	5.8 (4.3–7.9)	8.7 (4.8–15.3)	14.5 (11.0–18.9)	7.5 (5.5–10.1)	17.2 (13.8–21.3)	10.6 (8.4–13.3)	15.6 (12.3–19.6)	25.8 (21.1–31.3)	10.0 (8.1–12.4)	17.1 (13.9–20.9)	28.2 (25.0–31.6)	23.4 (17.0–31.3)	23.8 (17.4–31.7)	35.0 (29.7–40.7)	32.0 (30.5–33.6)
35–44	8.4 (5.6–12.3)	7.5 (5.9–9.5)	8.2 (6.3–10.8)	21.6 (18.0–25.6)	21.0 (17.7–24.7)	24.8 (21.7–28.3)	16.3 (13.0–20.2)	19.4 (15.7–23.6)	31.5 (26.2–37.3)	13.9 (11.2–17.2)	20.5 (16.9–24.7)	38.2 (35.1–41.4)	30.6 (24.0–38.0)	35.1 (27.7–43.2)	49.7 (44.8–54.6)	37.0 (35.5–38.5)
45–54	12.4 (9.7–15.6)	11.5 (9.2–14.2)	15.8 (12.4–20.0)	24.9 (20.9–29.5)	27.8 (23.2–33.0)	34.6 (31.0–38.4)	17.8 (14.9–21.2)	22.7 (18.9–27.0)	31.5 (26.7–36.6)	20.0 (17.0–23.5)	35.2 (30.9–39.9)	49.5 (46.5–52.5)	39.1 (32.2–46.4)	39.1 (34.7–53.0)	51.9 (56.2–56.2)	44.6 (43.1–46.1)
55–64	20.9 (16.6–26.1)	18.0 (14.7–21.7)	32.0 (24.9–40.1)	31.7 (26.0–38.0)	41.9 (35.6–48.6)	41.9 (37.8–46.0)	24.9 (20.9–29.4)	37.9 (32.7–43.3)	51.3 (45.4–57.1)	25.9 (22.1–30.2)	44.7 (38.5–51.2)	58.0 (54.5–61.5)	50.8 (42.0–59.5)	56.7 (47.7–65.2)	63.7 (60.2–67.1)	60.7 (59.4–62.0)
≥65	35.2 (29.6–41.3)	28.3 (24.1–32.8)	46.2 (38.0–54.7)	53.9 (47.1–60.5)	50.0 (42.1–58.0)	50.5 (46.5–54.4)	46.3 (40.3–52.3)	59.8 (54.1–65.2)	71.7 (65.6–77.2)	41.1 (35.5–47.0)	68.4 (62.2–74.0)	73.5 (70.4–76.4)	65.0 (58.0–71.3)	78.9 (72.2–84.3)	81.4 (78.8–83.7)	80.6 (79.6–81.6)
Women (≥15 years)																
Sample size	258	1302	110	116	546	559	1036	437	1367	81	772	5232	449	896	3369	35247
Population estimate (ever daily smokers), millions	13.3 (10.7–15.9)	12.5 (10.8–14.1)	1.1 (0.9–1.4)	0.6 (0.5–0.7)	3.1 (2.8–3.4)	1.1 (1.0–1.2)	13.5 (11.9–15.0)	2.8 (2.6–3.1)	5.7 (5.4–6.0)	0.2 (0.1–0.2)	4.5 (4.2–4.8)	17.5 (16.6–18.3)	2.7 (2.2–3.1)	0.4 (0.4–0.4)	9.5 (9.1–10.0)	38.6 (38.2–39.0)
Former smoking in ever daily smokers, %	16.8 (11.1–24.5)	16.2 (12.5–20.8)	41.3 (31.1–52.3)	28.6 (18.8–40.9)	25.0 (20.7–29.7)	34.4 (29.0–40.3)	17.1 (14.2–20.5)	25.0 (20.6–29.9)	33.7 (30.8–36.7)	21.2 (12.1–34.5)	23.9 (20.7–27.4)	47.7 (46.0–49.4)	33.1 (27.3–39.6)	41.0 (36.7–45.4)	51.4 (49.3–53.4)	50.5 (49.9–51.2)
Age (years)																
15–34	NA†	9.1 (2.8–25.9)	NA†	NA†	15.9 (8.8–26.8)	26.5 (16.3–40.1)	14.1 (10.6–18.6)	26.5 (20.8–33.1)	26.3 (21.1–32.1)	NA†	17.2 (13.1–22.1)	30.7 (27.6–33.9)	23.3 (16.5–31.8)	30.5 (23.8–38.1)	32.9 (29.1–37.1)	31.7 (30.4–33.1)
35–54	5.3 (2.2–12.4)	13.9 (9.5–19.9)	32.0 (16.5–52.9)	23.3 (11.3–42.1)	20.4 (14.8–27.4)	30.2 (21.8–40.1)	11.6 (8.3–15.9)	20.0 (14.2–27.3)	27.9 (24.2–32.0)	14.6 (6.5–29.6)	24.1 (19.3–29.7)	46.8 (44.3–49.3)	29.9 (22.8–38.3)	41.1 (34.2–48.4)	45.9 (42.8–49.1)	45.0 (43.8–46.1)
≥55	25.7 (17.3–36.5)	19.5 (13.8–26.8)	51.2 (34.5–67.7)	34.2 (19.7–52.5)	34.6 (26.9–43.1)	41.0 (33.4–49.1)	40.2 (29.1–52.5)	38.3 (22.6–56.8)	48.3 (42.2–54.3)	39.0 (20.5–61.4)	48.4 (37.7–59.4)	62.4 (59.3–65.3)	57.8 (43.9–70.6)	56.1 (48.2–63.6)	68.4 (65.9–70.9)	70.4 (69.5–71.2)

Data are n, n (95% CI), or % (95% CI). Data from the 2008–10 GATS,⁸⁰ 2008 General Lifestyle Survey (UK),⁸⁶ and the 2006–07 Tobacco Use Supplement to the Current Population Survey (USA).¹¹ Since there were very few female respondents who had ever smoked daily in some GATS countries, we only include three age groups for women in this table. Combining age categories reduced the number of cells with sample sizes of less than 25 individuals. NA=not available. GATS=Global Adult Tobacco Survey. *GATS measured former smoking in ever daily smokers; the UK study⁸⁶ measured former smoking in men who ever regularly smoked cigarettes, cigars, or pipes, and women who ever regularly smoked cigarettes or cigars; and the Tobacco Use Supplement to the Current Population Survey that measured the proportion of individuals who had ever smoked at least 100 cigarettes in their lifetimes who no longer smoke cigarette, cigars, or pipes. †Estimate not reported because sample size was <25 individuals.

Table 4: Percentage of ever daily smokers (and ever regular smokers)* who are former smokers, by sex and age, in the UK, USA, and 14 GATS countries

smokers and 247 million smokeless tobacco users (56 million smoked and used smokeless tobacco). Of 572 million cigarette smokers, 542 million smoked manufactured cigarettes (82% of all smokers and 64% of tobacco users). The number of tobacco users was highest in China (300·8 million) and India (274·9 million). China had the most smokers of any tobacco product (300·7 million), 284·9 million (94·7%) of whom smoked manufactured cigarettes. India had the most smokeless tobacco users (205·9 million).

Overall in GATS countries, 48·6% (95% CI 47·6–49·6) of men and 11·3% (10·7–12·0) of women were tobacco users; 40·7% (39·6–41·8) of men and 5·0% (4·7–5·3) of women were smokers; and 11·7% (11·0–12·4) of men and 6·7% (6·2–7·2) of women used smokeless tobacco (appendix p 16).

Table 2 and appendix pp 22–27 show age-specific patterns of current smoking. Prevalence in men generally increased into young adulthood or middle age and then declined. In women, we noted differing patterns. In Asian countries and Egypt, prevalence of smoking in women was very low and increased with increasing age. In Poland, Turkey, Brazil, and USA, smoking prevalence increased into young adulthood or middle age and then declined. In other nations, female smoking prevalence was consistently high among young people and declined progressively in older age groups.

For individuals who ever smoked daily, the relative average age of smoking start was older for women than it was for men as age category increased (table 3, appendix pp 28–33). For individuals aged 25–34 years, the mean age of initiation was much the same for both sexes. However, for individuals aged 35 years or older, the average age of initiation was generally older in women than men. All but two of 28 estimates of average age of start of smoking in 25–34 year olds were when individuals were younger than 20 years old. Estimates of average age of initiation of older than 20 years were more common in older cohorts.

We examined prevalence of current smoking in individuals aged 15–34 years with 5-year age categories (appendix pp 34–37). In male smokers aged 15–19 years, prevalence ranged from 5·4% (95% CI, 4·1–7·1) in India to 37·9% (32·2–43·9) in Russia; in female smokers aged 15–19 years, prevalence ranged from 0·0% in Bangladesh and Vietnam to 19·7% (13·8–27·3) in Russia. The prevalence ratio for individuals aged 20–24 years versus 15–19 years was striking for several countries. In male smokers, for example, the prevalence of current smoking in individuals aged 20–24 years in China and Vietnam was 3·5 times that of those aged 15–19 years. Prevalence in female smokers aged 20–24 years in Turkey was seven times that of those aged 15–19 years. This ratio was only less than 1·0 for Chinese women.

Table 4 and appendix p 38 show GATS data for proportion of persons who ever smoked daily and were former smokers at the time of their survey (ie, were

abstinent). In general, prevalence of former smoking in ever daily smokers increased with increasing age. Data in appendix pp 39–41 suggest that substantial differences exist in crude as compared with age-standardised estimates of quitting in Bangladesh, Brazil, UK, and the USA. For example, the age-standardised estimate was lower than the crude estimate by 13·5 percentage points for Bangladeshi women and by 11·6 percentage points for men in the UK. In both the crude and age-standardised data, quit ratios were low in China, India, Egypt, Russia, and Bangladesh (<20% overall), and substantially higher in the UK, USA, Brazil, and Uruguay (>35%).

Discussion

We report data that depict the global epidemic of tobacco use at the start of the 21st century. Collectively, GATS data and surveys from the UK and USA document the enormity of the epidemic and reinforce the need for effective tobacco control (panel 2). Of about 3 billion individuals aged 15 years or older living in the UK, USA, and 14 GATS countries, we estimated that 852 million were tobacco users, including 301 million in China and 275 million in India. Several general patterns can be identified across the surveys that have implications for tobacco-control strategies: smoking disproportionately affects men throughout the world; smoking rates remain lower in women than in men and prevalence is particularly low in women in Asia but is high in Poland, Russia, and the UK; women are increasingly starting to smoke at an equivalent age to men; quit ratios are highest in the UK, USA, and Brazil, but only a small proportion of smokers have stopped in several countries, including China and India; smokeless tobacco use is particularly prevalent in India and Bangladesh and in Thai women; and most tobacco users smoke manufactured cigarettes.

Most studies documenting the risks of cigarette smoking have been undertaken in smokers of manufactured cigarettes,¹⁷ by far the most widely used product, as documented in GATS. These products are technologically designed to mask harshness, provide particular taste sensations, and increase nicotine delivery.^{18–20} In addition, the tobacco companies that manufacture these cigarettes use numerous marketing and other strategies throughout the world to increase and sustain consumption.^{21,22}

Use of smokeless tobacco and bidis was especially common in India and Bangladesh, where individuals favour two products for chewing, betel with tobacco and tobacco mixed with lime. Both of these products are carcinogenic to human beings²³ and the rates of oral cancer in south-central Asia are among the highest in the world.²⁴ About 52% of oral cancers in India are attributable to the use of smokeless tobacco products.²⁵ Bidis produce risks for several diseases that are at least as high as those for manufactured cigarettes.^{26,27} Bidis are cheap alternatives to

manufactured cigarettes, because of substantially reduced taxation. They are frequently smoked by poor people who are often illiterate, malnourished, and unaware of the risks. Until recently bidis carried no warning whatsoever.²⁸

Our analysis of GATS suggested relatively high levels of waterpipe usage in Vietnam and Russia, which is a finding not previously reported in the scientific literature.²⁹ Use of hand-rolled cigarettes, a cheaper alternative to manufactured cigarettes, was most common in Thailand, where they were most likely to be smoked by rural, older, less educated, and poorer smokers.³⁰

In terms of regional and sex differences, rates of smoking in men in the UK and USA were among the lowest reported. In women, however, rates in the UK and USA were among the highest reported. In men, smoking was very common in Central and Eastern Europe. Rates of lung cancer in men are very high in Hungary, Poland, and Russia.³¹ Unless effective tobacco control measures are implemented soon, the future disease burden in Russia, Ukraine, and Turkey will probably be influenced by the high rates of smoking in adolescents and young adults of both sexes in those nations.

With the exception of women in Asian countries and Egypt, the age-specific prevalence of smoking was highest in young adulthood and middle age. A reduced prevalence of smoking in older age groups might be attributable to differential mortality (ie, individuals who did not quit smoking were less likely to survive to older ages) or to a cohort effect (ie, smoking prevalence was lower when individuals were young and they did not start smoking). The reduced prevalence in older individuals might also have been attributable to increased quitting on their part, as they became increasingly aware of the health consequences of smoking.

To reduce the epidemic of diseases caused by tobacco use, countries need to reduce the rate of starting, increase quit attempts and successful cessation, and protect non-smokers. Alarmingly, this study shows that—in most countries we surveyed—age of smoking initiation for women might now be approaching the young ages at which men begin. Many factors contribute to these changes, including the targeting of tobacco products to women via multiple media outlets, such as the cinema,^{21,32} and cigarette designs that ease the transition from experimentation to established use.¹⁸ Low prices and absence of effective counter-marketing campaigns also contribute to high rates of uptake.²

Quit ratios were low in most GATS countries and in some (eg, China, India, and Egypt) most male smokers do not intend to quit.² Quit ratios as low as those in China, India, Egypt, Bangladesh, and Russia have not been noted in the USA for more than 50 years.^{16,17} Countries with high quit ratios have undertaken effective public health education campaigns and have benefited from the early discontinuation of smoking by doctors and other health-care leaders.^{17,21} Price increases and access to affordable and effective cessation strategies also increase rates of quitting.²

Panel 2: Research in context

Systematic review

We searched PubMed for reports published before June 25, 2012, without language restriction with the keywords “country name” AND “smok*” AND “national*” AND “representative” entering the 14 GATS countries (China, Bangladesh, Brazil, Egypt, India, Mexico, Philippines, Poland, Russia, Thailand, Turkey, Ukraine, Uruguay, and Vietnam) in place of “country name”. We also replaced “representative” with “prevalence” in another search. From these searches and our previous work, we identified 21 studies estimating national smoking prevalence in GATS countries. Two studies^{33,14} reported more than one country. One included nationally representative surveys during 2001 and 2010 in eight countries of the former Soviet Union, including Russia and Ukraine.¹³ Another study reported smoking prevalence with data from 50 countries’ 2002–03 World Health Surveys.¹⁴ This study used an overall estimate of smoking prevalence from representative surveys in Bangladesh, Brazil, Mexico, Philippines, Turkey, Ukraine, Uruguay, and Vietnam. Data from more than 135 countries, using various surveys, are compiled by WHO³ and in The Tobacco Atlas.³ WHO also publishes reports with regional data.¹⁵

Interpretation

Our report expands previous work by estimating the prevalence of 15 indicators of tobacco use and cessation, by sex, in 14 low-income and middle-income countries that participated in Wave 1 of the Global Adult Tobacco Survey. It also permits comparisons with many similar indicators in the USA and the UK. GATS employs consistent and rigorous methodologies, permitting comparisons between countries and provides baseline data for monitoring of future trends. Our results document tobacco use in 852 million people (including 301 million in China and 275 million in India) and suggest that in many of the countries we surveyed the age of initiation of daily smoking among women seems to have become as young as it is in men and that smoking cessation in people in China, India, Egypt, Bangladesh, and Russia who have ever smoked daily is as low as was noted in the USA in the 1950s.^{16,17} This monitoring activity could help guide and assess future tobacco-control activities.

In 2011, tobacco control was identified as the “most urgent and immediate priority” intervention to reduce non-communicable diseases.³³ The United Nations high-level meeting on non-communicable diseases echoed the urgency of controlling of tobacco use. To reduce worldwide smoking prevalence by 30% by 2025, countries are exhorted to fully implement the Framework Convention on Tobacco Control.^{7,34} WHO defines optimum policies on smoke-free air, cessation, warning labels, mass media, marketing bans, and taxation, which, if fully implemented worldwide, would have an enormous effect on reduction of premature mortality.² Although 1.1 billion people have been covered by the adoption of the most effective tobacco-control policies since 2008, 83% of the world’s population are not covered by two or more of these policies.²

This study had limitations. The data used in this report were based on self-report and thus are subject to misclassification bias: however, estimates obtained from population-based surveys that use self-report are generally valid, apart from when there is a high demand for abstinence.^{35,36} In some countries, where smoking is socially unacceptable in women or young people, household-based estimates of smoking prevalence made

on the basis of self-report might underestimate the true prevalence. The number of cigarettes smoked every day might also be under-reported. Furthermore, the first wave of GATS did not include several low-income and middle-income countries (eg, Indonesia, Pakistan, and Nigeria) with large populations of smokers. Indonesia and Nigeria are participating in the second wave of GATS and Pakistan is scheduled to participate in Wave 3. Comparability of indicators from the General Lifestyle Survey and Tobacco Use Supplement with those from GATS might be limited by differences in the questionnaire content and sampling techniques, and by the relatively low response rate (56.9%) in the Tobacco Use Supplement.

Our findings from the first wave of GATS come at a crucial point in tobacco control, several years after the ratification of the Framework Convention on Tobacco Control. The use of a standardised method will be especially important as countries monitor their trends over time. GATS has already been repeated in Thailand and Turkey and it will be repeated in all Wave 1 countries in the coming years. GATS has been expanded to 17 new countries, and many others have expressed interest. Wave 1 results document the heterogeneity of the tobacco epidemic across the world and the diverse challenges for tobacco control, particularly the need to reduce or maintain low smoking rates among women, to reduce initiation by young people, and to increase quitting rates in all smokers.

In part because of the first wave of GATS, almost half of the world's population is receiving adequate monitoring of tobacco use.² A 22-item subset of questions, called *Tobacco Questions for Surveys*, is available for nations unable to undertake the entire survey.³⁷ A subset of these questions can also be recommended on the basis of country-specific needs. Another technique for assessment purposes is the International Tobacco Control Policy Evaluation Project, which is designed to assess Framework Convention on Tobacco Control policies by use of cohort studies with several country controls.³⁸

The first wave of GATS showed that comparable nationally representative data can be obtained in 14 low-income and middle-income countries. These surveys address capacity needs of countries¹⁵ and should be used to promote implementation of effective strategies for tobacco control.^{2,4}

Contributors

GAG, SAM, JMS, and PCG were principally responsible for writing of the paper. GAG, SAM, JMS, PCG, NB, and RP designed the presentation of the study with input from all other authors. GAG took the lead on analysis and interpretation of all findings with support from SAM. JH and KMP were involved in Global Adult Tobacco Survey (GATS) survey sampling design and GAG and JM were involved in GATS survey questionnaire design, with input from PCG and WZ. MJ analysed and took the lead for all General Lifestyle Survey data. GAG took the lead for all US Tobacco Use Supplement to the Current Population Survey data. SAM, JH, JM, and KMP provided input and technical support for GATS data collection along with members of the GATS Collaborative Group. SA was responsible for obtaining funding

and overall project collaboration. GAG and SAM did literature searches and finalised the references. GAG and SAM led subsequent revisions with all authors providing reviews of and comment on successive drafts.

Conflicts of interest

We declare that we have no conflicts of interest.

Acknowledgments

The views expressed in this Article are solely those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC) or the Global Adult Tobacco Survey partner organisations. Technical assistance was provided by the US CDC, Regional Offices of WHO, Johns Hopkins Bloomberg School of Public Health, University of North Carolina at Chapel Hill, and RTI International. Programme support was provided by the CDC Foundation. The General Lifestyle Survey was funded by the British Government. The Tobacco Use Supplement to the Current Population Survey was sponsored by the US Government (National Cancer Institute and CDC). GAG, JMS, PCG, and WZ were supported by the CDC Foundation. RP, NB, and MJJ received no outside funding for their work on this project. SAM, JH, KMP, and SA are employees of the US Government (CDC). JM is a contractor to CDC. We are particularly grateful to Glenda Blutcher-Nelson (contractor to CDC) for programming and analyses of GATS datasets, Angela Troclair (CDC) for programming and analysis of the US Tobacco Use Supplement to the Current Population Survey datasets, Jessica Kulak (University at Buffalo, NY, USA) for assistance with editing and the creation of tables and figures, Jane Zanca (CDC, National Center for Chronic Disease Prevention and Health Promotion) for editorial comments, and Edward Raine (contractor to CDC) for assistance with the creation of some figures. We thank the thousands of fieldworkers for their contributions and the survey respondents for their co-operation, without whom this work would not have been realised, and the members of the GATS Collaborative Group for all of their expertise and contributions.

References

- 1 WHO. Global health risks: mortality and burden of disease attributable to selected major risks. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf (accessed June 25, 2012).
- 2 WHO. WHO report on the global tobacco epidemic: 2011. Geneva: World Health Organization, 2011.
- 3 Eriksen M, Mackay J, Ross H. The tobacco atlas, 4th edn. Atlanta, GA, USA: American Cancer Society, 2012.
- 4 Giovino GA, Biener L, Hartman AM, et al. Monitoring the tobacco use epidemic I. Overview: optimizing measurement to facilitate change. *Prev Med* 2009; 48: S4–10.
- 5 Warren CW, Asma S, Lee J, Lea V, Mackay J. Global Tobacco Surveillance System—the GTSS atlas. Atlanta, GA, USA: CDC Foundation, 2009.
- 6 Centers for Disease Control and Prevention. Global Tobacco Surveillance System. <http://www.cdc.gov/tobacco/global/gtss/index.htm> (accessed Feb 3, 2012).
- 7 WHO. WHO Framework Convention on Tobacco Control. Geneva: World Health Organization, 2005.
- 8 Kalsbeek WD, Bowling JM, Hsia J, et al. The Global Adult Tobacco Survey (GATS): sample design and related methods. https://www.amstat.org/sections/SRMS/Proceedings/y2010/Files/307559_58832.pdf (accessed June 25, 2012).
- 9 Global Adult Tobacco Survey Collaborative Group. Global Adult Tobacco Survey (GATS): quality assurance: guidelines and documentation, version 2.0. <http://apps.nccd.cdc.gov/gtssdata/Ancillary/Documentation.aspx?SUID=4&DOCT=1> (accessed July 12, 2012).
- 10 Office for National Statistics. General Lifestyle Survey. Technical appendices 2009. <http://www.esds.ac.uk/doc/6737%5Cmrdoc%5Cpdf%5C6737appendices.pdf> (accessed Feb 6, 2012).
- 11 US Department of Commerce, Census Bureau 2008, National Cancer Institute and Centers for Disease Control and Prevention. Tobacco use supplement to the current population survey 2006–2007. <http://riskfactor.cancer.gov/studies/tus-cps> (accessed May 18, 2011).

- 12 Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. GPE discussion paper series: no 31. <http://www.who.int/healthinfo/paper31.pdf> (accessed July 12, 2012).
- 13 Roberts B, Gilmore A, Stickley A, et al. Changes in smoking prevalence in 8 countries of the former Soviet Union between 2001 and 2010. *Am J Public Health* 2012; **102**: 1320–28.
- 14 Harper S, McKinnon B. Global socioeconomic inequalities in tobacco use: internationally comparable estimates from the World Health Surveys. *Cancer Causes Control* 2012; **23**: 11–25.
- 15 Alwan A, Maclean DR, Riley LM, et al. Monitoring and surveillance of chronic, non-communicable diseases: progress and capacity in high burden countries. *Lancet* 2010; **376**: 1861–68.
- 16 Haenszel W, Shimkin MB, Miller HP. Tobacco smoking patterns in the United States: public health monograph 45. Washington, DC: US Public Health Service publication 463, Department of Health, Education, and Welfare, Public Health Service, 1956.
- 17 US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the surgeon general. Rockville, MD, USA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989: 89–8411.
- 18 Cummings KM, Morley CP, Horan JK, Steger C, Leavell N-R. Marketing to America's youth: evidence from corporate documents. *Tob Control* 2002; **11** (suppl 1): i5–17.
- 19 Ashley DL, Pankow JF, Tavakoli AD, Watson CH. Approaches, challenges, and experience in assessing free nicotine. In: Henningfield JE, London ED, Pogun S, eds. Nicotine psychopharmacology. Handbook of experimental pharmacology 192. Berlin: Springer-Verlag, 2009.
- 20 Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 3241–62.
- 21 National Cancer Institute. The role of the media in promoting and reducing tobacco use. Tobacco control monograph 19. Bethesda, MD, USA: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2008.
- 22 Asma S, Bettcher DW, Samet J, et al. Tobacco. In: Detels R, McEwen R, Beaglehole R, Tanaka H, eds. Oxford textbook of public health, 4th edn. Oxford: Oxford University Press, 2009.
- 23 IARC. Tobacco habits other than smoking; betel-quit and areca nut chewing; and some related nitrosamines. In: IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 37. Lyon, France: International Agency for Research on Cancer, 1985.
- 24 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69–90.
- 25 Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. *Lancet Oncol* 2008; **9**: 667–75.
- 26 Gupta PC, Asma S. Bidi smoking and public health. New Delhi: Ministry of Health and Family Services, Government of India, 2008.
- 27 Jha P, Jacob B, Gajalakshmi V, et al, for the RGI-CGHR investigators. Case-control study of smoking and death in India. *N Engl J Med* 2008; **358**: 1137–47.
- 28 Ministry of Health and Family Welfare (Department of Health and Family Welfare) Notification. Amendment to India's cigarettes and other tobacco products act (packaging and labeling). New Delhi: The Gazette of India, 2011.
- 29 Akl EA, Gumukula SK, Aleem S, et al. The prevalence of waterpipe tobacco smoking among the general and specific populations: a systematic review. *BMC Public Health* 2011; **11**: 244.
- 30 WHO Regional Office for South-East Asia. Global Adult Tobacco Survey (GATS): Thailand country report, 2009. http://www.searo.who.int/LinkFiles/Regional_Tobacco_Surveillance_System_GATS_Thailand_2009.pdf (accessed May 18, 2011).
- 31 Youlten DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. *J Thorac Oncol* 2008; **3**: 819–31.
- 32 Choudhury S, Kengganpanich M, Benjakul S, et al. Differences by sex in tobacco use and awareness of tobacco marketing—Bangladesh, Thailand, and Uruguay, 2009. *MMWR Morb Mortal Wkly Rep* 2010; **59**: 613–18.
- 33 Beaglehole R, Bonita R, Horton R, et al, for The Lancet NCD Action Group and the NCD Alliance. Priority actions for the non-communicable disease crisis. *Lancet* 2011; **377**: 1438–47.
- 34 WHO. A comprehensive global monitoring framework including indicators and a set of voluntary global targets for the prevention and control of noncommunicable diseases. Second WHO discussion paper (version dated 22 March 2012). http://www.searo.who.int/LinkFiles/mhnd_GMF.pdf (accessed June 25, 2012).
- 35 IARC. IARC handbooks of cancer prevention: tobacco control, volume 12. Methods for evaluating tobacco control. Lyon, France: International Agency for Research on Cancer, 2008.
- 36 Jung-Choi KH, Khang YH, Cho HJ. Hidden female smokers in Asia: a comparison of self-reported with cotinine-verified smoking prevalence rates in representative national data from an Asian population. *Tob Control* 2011; published online Oct 4. DOI:10.1136/tobaccocontrol-2011-050012.
- 37 Global Tobacco Surveillance System (GTSS). Tobacco questions for surveys: a subset of key questions from the Global Adult Tobacco Survey (GATS), 2nd edition. <http://www.who.int/tobacco/surveillance/tqs/en/index.html> (accessed April 18, 2012).
- 38 International Tobacco Control Policy Evaluation Project. Surveys and project protocols. <http://www.itcproject.org> (accessed May 18, 2011).

Curtailing tobacco use: first we need to know the numbers

Data, transformed through aggregation and analysis into useful information, are key elements for decision making. This notion is true in general and has become a precept for promotion of health and control of disease. Tobacco use globally is the main preventable contributor to poor health and premature death.¹ In *The Lancet*, Gary Giovino and colleagues² describe the acquisition of high-quality data for tobacco use from 14 countries through the employment of well-designed and well-implemented surveys, the Global Adult Tobacco Survey (GATS), with 16 countries studied in total. GATS was originally developed by the US Centers for Disease Control and Prevention (CDC) and has been widely applied by host countries working with CDC and WHO.

Accurate data are needed on the characteristics of tobacco users (eg, age, sex, income, and occupation), how tobacco is used (smoking cigarettes, bidis, or water pipes vs chewing tobacco or taking snuff), and where and why people use tobacco. Such data are vital for planning purposes, such as designing interventions and targeting at-risk groups, and for evaluation and programme

assessment purposes, such as establishment of the baseline and examination of data after an intervention has been applied (ie, whether or not an intervention works). Effective policy development and assessment depend on such data and information.

Thus, a reliable measurement technique that can be used by all countries to obtain this information has been desperately needed to address the huge global health threat of tobacco use. GATS offers such a technique: the standardised questionnaires it employs enable, for the first time, comparative data analysis. Impressively, GATS already covers more than half the world's population.

Giovino and colleagues' report² offers a spectrum of global tobacco use, and the differences between nations are interesting and important. Although many more men than women smoke in all countries surveyed, the prevalence of current smoking for women varies greatly, from 0.5% in Egypt to 24.4% in Poland. How people use tobacco varies substantially, as does the age at which people start tobacco use. These data are not static. With behaviours and lifestyle in flux globally and marketing



See [Articles](#) page 668

rampant, we can expect initiation of tobacco use to begin at younger ages than at present, and pressures on young women to smoke to increase. Hopefully, with successful control efforts, there will be an increase in attempted and successful quit rates. Thus, repeated GATS or their equivalent will be an essential element of tobacco control.

In view of the health burden of tobacco use, the underinvestment in tobacco control is extraordinary. For example, core funding by governments for implementing the WHO Framework Convention on Tobacco Control (FCTC) within their own countries is woefully inadequate for the enormity of the epidemic.³ For example, in low-income countries, for every US\$9100 received in tobacco taxes, only \$1 was spent on tobacco control. However, effective tobacco-control approaches have been seen with huge health and economic benefits in many countries. Through multiple educational, mass media, policy, and regulatory efforts, smoking prevalence in Hong Kong has declined over 50% from 1982 to 2008.⁴ Whether the WHO approaches to tobacco control (FCTC and MPOWER⁵) are used, or other similar schemes of effective control and prevention interventions—such as smoke-free legislation and enforcement, increased tobacco taxation, increases in population knowledge of tobacco risks, and changes in population attitude toward the social acceptability of smoking and the value and feasibility of quitting—proven techniques exist to diminish tobacco use. The Bloomberg Philanthropies' Initiative and the Bill & Melinda Gates Foundation deserve great credit for tackling this major health threat, and their continued interest and role will be crucial to the success of tobacco control. Beyond the financial investment and introduction of technical assistance, their interest encourages governmental attention to tobacco control and improves the evidence base and scientific quality of control efforts, as seen in support for GATS. Nevertheless, interest and investment in tobacco control need to extend beyond two philanthropic organisations and involve governments at many levels, other philanthropic groups, and global health and development agencies.

The main challenge is how to translate the findings from GATS and other surveys into health policy. Many

governments do not instinctively reach for data when designing policy. Assumptions that research findings will lead to policy change, basing policy on evidence, are overly optimistic, whether in high-income countries, where political factors can override scientific evidence, or in low-income and middle-income countries, which might not have a tradition of linking research and data to decision making.⁶

Few policy makers have the scientific background to assess the validity and quality of even the high quality data of GATS. Governments might also reason that scientific evidence is only one aspect of designing policy. They suggest that they have to listen to all opinion, including the tobacco industry and public (who can be poorly informed).⁷

The need to bridge the existing gaps between research, policy, and practice is a global phenomenon. Three resolutions—the Mexico Action Statement on Health Research in 2004 (58 countries), the related World Health Assembly resolution in 2005 (193 countries), and the Bamako Call to Action on Research for Health in 2008 (53 countries)—urged researchers, policy makers, and health care providers to collaborate in efforts to bridge these gaps.⁸

**Jeffrey P Koplan, Judith Mackay*

Emory Global Health Institute, Emory University, Atlanta, GA 30322, USA (JPK); and World Lung Foundation, Hong Kong Office, Hong Kong, China (JM)
jkoplan@emory.edu

JPK receives support from the Gates Foundation for a project on tobacco control in China. JM declares that she has no conflicts of interest.

- 1 Eriksen M, Mackay J, Ross H. The tobacco atlas, 4th edn. Atlanta, GA: American Cancer Society and New York, NY: World Lung Foundation, 2012.
- 2 Giovino GA, Mirza SA, Samet JM, et al, for The GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet* 2012; **380**: 668–79.
- 3 Ross H, Stoklosa M. Development assistance for global tobacco control. *Tob Control* 2011; published online June 15. DOI:10.1136/tc.2011.043380.
- 4 Koplan JP, Wang KA, Lam RMK. Hong Kong: a model of successful tobacco control in China. *Lancet* 2010; **375**: 1330–31.
- 5 WHO. WHO MPOWER. <http://www.who.int/tobacco/mpower/en/> (accessed Aug 2, 2012).
- 6 Carden C. Knowledge to policy: making the most of development research. CA, USA: Sage, 2009.
- 7 Oliver TR. The politics of public health policy. *Ann Rev Public Health* 2006; **27**: 195–233.
- 8 Lavis JN, Guindon GE, Cameron D, et al, for the Research to Policy and Practice Study Team. Bridging the gaps between research, policy and practice in low- and middle-income countries: a survey of researchers. *CMAJ* 2010; **182**: E350–61.